• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / U.S. Equity

How to Scour for Attractive Ideas, Part 2

Here are two names I liked out of 200.
By SHAM GAD Dec 10, 2014 | 02:00 PM EST
Stocks quotes in this article: SZMK, UTMD

Yesterday, I talked all about the work involved in finding attractive investment ideas. While I strongly believe in teaching a man how to fish as opposed to catching the fish for him, part of the advantages of coming to Real Money is to get a peek at some investment ideas. Not to mention, it's easy for me to simply tell you what you already know; I should also be able to back it up. So here goes.

As I pour through dozens of securities each week, 90% are dismissed within the first 10 minutes. What makes the cut and constitutes the other 10%?

Well, one such name is small-cap Sizmek (SZMK), a technology company that provides a comprehensive online advertising solution. I have previously talked about the qualitative merits. In addition, what jumps out is that the company is trading at 70% of book value, has no debt and half of its market value consists of cash. It's a $6 security with $3 in net cash per share, implying an enterprise value of $90 million. Free cash flow in 2013 was $12 million and that was a very depressed figure. I believe you can figure out the math.

Utah Medical Products (UTMD) is another name that I found from flipping page after page inValue Line. I still need to look closer but on the surface, there's a lot to like. The company makes and sells medical products that support intensive care, obstetrics and other critical medical needs. The company has a market cap of $216 million, $6 million in debt and $18 million in cash. Profit margins are a juicy 28% and return on equity is 20%. The company churns out healthy free cash flows each year with little to no capital expenditures. I aim to find out more.

I would estimate that I had to look at more than 200 securities before finding these two names. One came from an investor's 13F and one came at the very end of an edition of Value Line (the good stuff is usually at the very end). They never come to you when you have  have only looked at two securities. It's not a bad time to look closer.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gad was long SZMK.

TAGS: Investing | U.S. Equity

More from U.S. Equity

Have You Noticed This Shift in the Market?

James "Rev Shark" DePorre
May 25, 2022 11:00 AM EDT

Bonds tend to gain strength, and interest rates decline as worries about a recession increase.

Investor Sentiment Remains at Historically High Levels of Fear

Guy Ortmann
May 25, 2022 10:15 AM EDT

Here's where things stand in this volatile stock market.

Snap Judgement, S&P Basing Pattern? Spiraling Macro, Trading Lithium Stocks

Stephen Guilfoyle
May 25, 2022 7:49 AM EDT

A lot of folks haven't even realized that their 401(k)s and IRAs have been 'smashified' -- and that their homes are not worth what they think.

Overnight Blood, Didn't It Matter? Snap's Whammy, Trading Bank Stocks and Zoom

Stephen Guilfoyle
May 24, 2022 7:35 AM EDT

There was the 'momentum play' on Monday and not much else as portfolio managers resisted temptation to increase risk exposure.

Bottom Fishing for Biotech Bargains

Bret Jensen
May 23, 2022 11:45 AM EDT

Here are three names I have added to in May.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login